1984
DOI: 10.1016/s0190-9622(84)80323-0
|View full text |Cite
|
Sign up to set email alerts
|

The treatment of Sézary syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
30
0
1

Year Published

1988
1988
2015
2015

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 65 publications
(31 citation statements)
references
References 6 publications
0
30
0
1
Order By: Relevance
“…77 Other recommended treatment options include immunotherapy, BRMs, and chlorambucil plus prednisone. 136 The pertinent studies have been discussed above and are cited in Table 11. 12.6.2. Second-line recommendations 12.6.2.1.…”
Section: Chemotherapy Many Different Chemotherapeuticmentioning
confidence: 99%
“…77 Other recommended treatment options include immunotherapy, BRMs, and chlorambucil plus prednisone. 136 The pertinent studies have been discussed above and are cited in Table 11. 12.6.2. Second-line recommendations 12.6.2.1.…”
Section: Chemotherapy Many Different Chemotherapeuticmentioning
confidence: 99%
“…For the temozolomide study, 47 the follow-up was very short (6-9 months), explaining the reported short duration of response. And for the oldest studies, 45,50 the duration of response was not specified. In summary, the present prospective study demonstrates the effectiveness of pegylated liposomal doxorubicin in treating CTCL, showing a response rate of 53% in refractory, frequently advanced cases.…”
Section: Commentmentioning
confidence: 99%
“…With combination chemotherapy, the response rates are high but duration of response may be short-lived. 21,[224][225][226][227][228] In 1974, Winkelmann et al first advocated the use of oral low-dose chlorambucil and prednisolone as a relatively non-toxic chemotherapeutic option for palliation of Sézary syndrome. In 21 patients treated with this regimen, the OR rate was 57% with 3 complete responders (14%).…”
Section: Combination Chemotherapymentioning
confidence: 99%
“…In 21 patients treated with this regimen, the OR rate was 57% with 3 complete responders (14%). 224 CVP (cyclophosphamide, vincristine, prednisone), CVPB (cyclophosphamide, vincristine, prednisone, and bleomycin), and CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) have also been effective in MF. 225,226 In 1998, Hallahan et al treated patients with T3 stage MF with TSBEB and MOPP (methotrexate, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone) and reported a 70% OR rate and 14 month duration of response.…”
Section: Combination Chemotherapymentioning
confidence: 99%